NeuroOne Expands Global Patent Portfolio with Key Approvals for Neurological Technology

NeuroOne Medical Technologies Corporation has significantly expanded its intellectual property portfolio with recent patent approvals from both the United States and European patent offices. The medical technology company, focused on improving surgical care for neurological disorders, announced three key patent developments that strengthen its position in the neurological device market.

The United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 17/860,232 on September 29, 2025. This patent, titled "Probe Devices with Temperature Sensors and Related Systems and Methods," covers novel electrode devices featuring at least one electrode contact and a temperature sensor. A Notice of Allowance indicates the USPTO's determination that a patent should be granted following examination, with NeuroOne anticipating formal issuance in the coming months.

On October 1, 2025, the European Patent Office granted European Patent 4013481, titled "Spinal Cord Stimulation Systems, Methods, and Devices." This represents NeuroOne's first granted patent in Europe and covers novel spinal cord stimulation devices with a deployable electrode array body. The European approval marks a significant milestone in the company's international expansion strategy.

The USPTO further strengthened NeuroOne's portfolio on October 7, 2025, with the issuance of U.S. Patent 12,435,407. This patent, titled "Methods for Making Probe Devices and Related Devices," covers novel manufacturing methods for neural probe and spinal cord stimulation devices. It includes specific steps for arranging probe components and depositing electrode contact material, potentially enhancing production efficiency and device quality.

These recent additions complement NeuroOne's existing portfolio, which includes four additional issued U.S. patents, seven pending U.S. applications, and eight pending foreign applications. The portfolio covers various thin-film electrode technologies, including both neural and spinal cord electrodes with unique structures designed to optimize functionality while minimizing device profiles.

Dave Rosa, NeuroOne's chief executive officer, emphasized the strategic importance of these developments. "NeuroOne has made tremendous progress expanding our robust patent portfolio," Rosa stated. "Our goal is to continue to grow our technology platform to broader use cases and applications. Temperature Control is an integral feature of our OneRF Ablation System that provides a critical safety measure for brain ablations for patients suffering from seizures."

The European patent specifically addresses a percutaneously placed paddle electrode designed to treat lower back pain without requiring surgical incisions. This innovation could significantly impact patient care by reducing procedural invasiveness and recovery times for chronic pain sufferers. The temperature sensor technology covered by the U.S. patent application represents another important safety advancement for brain ablation procedures used in treating epilepsy and other neurological conditions.

These patent developments signal NeuroOne's continued commitment to advancing neurological treatment options while building substantial intellectual property barriers against competition. The expanded patent protection could facilitate broader adoption of the company's technologies across multiple therapeutic areas, potentially improving outcomes for patients with epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain conditions. The international patent coverage also positions NeuroOne for global market expansion, particularly in European healthcare markets where minimally invasive neurological treatments are increasingly sought after.